Aims:To assess the impact of drug-eluting stents (DES) compared to bare-metal stents (BMS) for the endovascular treatment of atherosclerotic renal artery stenosis (ARAS).
Methods: We retrospectively evaluated all of our endovascular BMS- and DES-implantations performed in de-novo ARAS between 2000-2014 at our institution. The occurrence of in-stent restenosis (ISR) detected by ultrasound or angiography, kidney function, blood pressure (BP), and the number of antihypertensive drugs were analyzed as endpoints.
Results: Overall, 338 renal arteries were treated in 298 patients. BMS…